{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:13Z","timestamp":1761513313993},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T00:00:00Z","timestamp":1372464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00280-013-2222-x","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T18:16:39Z","timestamp":1372443399000},"page":"463-470","source":"Crossref","is-referenced-by-count":43,"title":["A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis"],"prefix":"10.1007","volume":"72","author":[{"given":"Masafumi","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Mitsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Yamaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,29]]},"reference":[{"key":"2222_CR1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118\u20131127","journal-title":"N Engl J Med"},{"key":"2222_CR2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245\u20131255","journal-title":"Lancet"},{"key":"2222_CR3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M (2011) Management of hepatocellular carcinoma in Japan: consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339\u2013364","journal-title":"Dig Dis"},{"key":"2222_CR4","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Kaneko S (2012) Treatment strategies for hepatocellular carcinoma in Japan. Hepatol Res. doi: 10.1111\/j.1872-034X.2012.01029.x","journal-title":"Hepatol Res"},{"key":"2222_CR5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"2222_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"2222_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821\u2013829","journal-title":"J Hepatol"},{"key":"2222_CR8","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","volume":"48","author":"AL Cheng","year":"2012","unstructured":"Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 48:1452\u20131465","journal-title":"Eur J Cancer"},{"key":"2222_CR9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0163-7258(83)90077-3","volume":"21","author":"WD Ensminger","year":"1983","unstructured":"Ensminger WD, Gyves JW (1983) Regional chemotherapy of neoplastic diseases. Pharmacol Ther 21:277\u2013293","journal-title":"Pharmacol Ther"},{"key":"2222_CR10","first-page":"1122","volume":"46","author":"EE Tzoracoleftherakis","year":"1999","unstructured":"Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK (1999) Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 46:1122\u20131125","journal-title":"Hepatogastroenterology"},{"key":"2222_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jjco\/hyq145","volume":"41","author":"M Kondo","year":"2011","unstructured":"Kondo M, Morimoto M, Numata K, Nozaki A, Tanaka K (2011) Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Jpn J Clin Oncol 41:69\u201375","journal-title":"Jpn J Clin Oncol"},{"key":"2222_CR12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cncr.10694","volume":"95","author":"E Ando","year":"2002","unstructured":"Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95:588\u2013595","journal-title":"Cancer"},{"key":"2222_CR13","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3748\/wjg.v9.i12.2666","volume":"9","author":"YC Lai","year":"2003","unstructured":"Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK (2003) Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 9:2666\u20132670","journal-title":"World J Gastroenterol"},{"key":"2222_CR14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.hepres.2005.01.015","volume":"32","author":"JY Cheong","year":"2005","unstructured":"Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, Hahm KB, Kim JH (2005) Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 32:127\u2013133","journal-title":"Hepatol Res"},{"issue":"Suppl 1","key":"2222_CR15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000315244","volume":"78","author":"K Ueshima","year":"2010","unstructured":"Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H (2010) Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 78(Suppl 1):148\u2013153","journal-title":"Oncology"},{"key":"2222_CR16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bjc.6602742","volume":"93","author":"H Ota","year":"2005","unstructured":"Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M (2005) Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93:557\u2013564","journal-title":"Br J Cancer"},{"key":"2222_CR17","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/cncr.21832","volume":"106","author":"S Obi","year":"2006","unstructured":"Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M (2006) Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990\u20131997","journal-title":"Cancer"},{"key":"2222_CR18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-007-2099-8","volume":"42","author":"K Uka","year":"2007","unstructured":"Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K (2007) Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil\/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 42:845\u2013853","journal-title":"J Gastroenterol"},{"key":"2222_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000328281","volume":"80","author":"H Nagano","year":"2011","unstructured":"Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y, Mori M (2011) Long-term outcome of combined interferon-\u03b1 and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 80:63\u201369","journal-title":"Oncology"},{"key":"2222_CR20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000334439","volume":"81","author":"T Yamashita","year":"2011","unstructured":"Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S (2011) Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 81:281\u2013290","journal-title":"Oncology"},{"key":"2222_CR21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1056\/NEJM199505113321910","volume":"332","author":"Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire","year":"1995","unstructured":"Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1294\u20131296","journal-title":"N Engl J Med"},{"key":"2222_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","volume":"29","author":"G Pelletier","year":"1998","unstructured":"Pelletier G, Ducreux M, Gay F, Luboinski M, Hag\u00e8ge H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29:129\u2013134","journal-title":"J Hepatol"},{"key":"2222_CR23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164\u20131171","journal-title":"Hepatology"},{"key":"2222_CR24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","volume":"38","author":"M Yoshikawa","year":"2008","unstructured":"Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474\u2013483","journal-title":"Hepatol Res"},{"key":"2222_CR25","volume-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization (1979) WHO handbook for reporting results of cancer treatment, vol 48. World Health Organization, Geneva"},{"key":"2222_CR26","first-page":"1079","volume":"71","author":"R Simon","year":"1987","unstructured":"Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079\u20131085","journal-title":"Cancer Treat Rep"},{"key":"2222_CR27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1872-034X.2011.00905.x","volume":"42","author":"M Monden","year":"2012","unstructured":"Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E, FAIT Research Group (2012) 5-fluorouracil arterial infusion\u00a0+\u00a0interferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study. Hepatol Res 42:150\u2013165","journal-title":"Hepatol Res"},{"key":"2222_CR28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52\u201364","journal-title":"Gastroenterology"},{"key":"2222_CR29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, I\u00f1arrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S, European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54:868\u2013878","journal-title":"Hepatology"},{"issue":"suppl 1","key":"2222_CR30","first-page":"976A","volume":"48","author":"YK Kang","year":"2008","unstructured":"Kang YK, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Burock K, Zou J, Voliotis D, Cheng AL (2008) Sorafenib is effective in patients from the Asia-Pacific region with hepatocellular carcinoma (HCC): subgroup analysis of effect of macroscopic vascular invasion, extrahepatic spread, and ECOG performance status on outcome. Hepatology 48(suppl 1):976A (abstr 1505)","journal-title":"Hepatology"},{"key":"2222_CR31","first-page":"1684","volume":"28","author":"FS Chen","year":"2008","unstructured":"Chen FS, Cui YZ, Luo RC, Wu J, Zhang H (2008) Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 28:1684\u20131687","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"2222_CR32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/bjc.2012.539","volume":"108","author":"C Eicher","year":"2013","unstructured":"Eicher C, Dewerth A, Thomale J, Ellerkamp V, Hildenbrand S, Warmann SW, Fuchs J, Armeanu-Ebinger S (2013) Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Br J Cancer 108:334\u2013341","journal-title":"Br J Cancer"},{"key":"2222_CR33","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1200\/JCO.2009.27.7988","volume":"28","author":"W Sun","year":"2010","unstructured":"Sun W, Powell M, O\u2019Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd (2010) Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28:2947\u20132951","journal-title":"J Clin Oncol"},{"key":"2222_CR34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/annonc\/mds581","volume":"24","author":"C Xue","year":"2013","unstructured":"Xue C, Huang Y, Huang PY, Yu QT, Pan JJ, Liu LZ, Song XQ, Lin SJ, Wu JX, Zhang JW, Zhao HY, Xu F, Liu JL, Hu ZH, Zhao LP, Zhao YY, Wu X, Zhang J, Ma YX, Zhang L (2013) Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 24:1055\u20131061","journal-title":"Ann Oncol"},{"key":"2222_CR35","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","volume":"30","author":"LG Paz-Ares","year":"2012","unstructured":"Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A, NSCLC [non-small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine\/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084\u20133092","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2222-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2222-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2222-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:30Z","timestamp":1559038290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2222-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,29]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2222-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,29]]}}}